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Background-—Platelet activation is central to the pathogenesis of acute coronary syndromes. Surface expression of P-selectin on
activated platelets induces formation of platelet–monocyte aggregates and promotes vascular inflammation and thrombosis.
P-selectin antagonism may represent a novel therapeutic strategy in vascular disease. We aimed to investigate the effects of the
novel P-selectin antagonist PSI-697 on platelet–monocyte aggregate formation in humans.
Methods and Results-—In a double-blind, randomized, placebo-controlled crossover study, healthy smokers were randomized to
receive either oral PSI-697 600 mg or matched placebo. The sequence of treatment was also randomized, with all subjects
receiving both PSI-697 and placebo. Platelet–monocyte aggregates were measured by flow cytometry at 4 and 24 hours in the
presence and absence of thrombin receptor-activating peptide (TRAP; 0.1 to 1.0 lm/L). The ex vivo addition of TRAP caused a
concentration-dependent increase in platelet–monocyte aggregates from 8.2% to 94.8% (P<0.001). At 4 and 24 hours, plasma
concentrations of PSI-697 increased to 1906 and 83 ng/mL, respectively (P<0.001). PSI-697 had no demonstrable effect on either
stimulated or unstimulated platelet–monocyte aggregates at 4 or 24 hours (P>0.05). P-selectin-blocking antibody (CLB-Thromb6),
but not PSI-697, inhibited both stimulated and unstimulated platelet–monocyte aggregate formation in vitro (P<0.001).
Conclusions-—The novel small-molecule P-selectin antagonist PSI-697 did not inhibit basal or stimulated platelet–monocyte
aggregate formation in humans at the dose tested. Its clinical efficacy remains to be established.
Clinical Trial Registration-—URL: http://EudraCT.ema.europa.eu Unique identifier: 2007-005695-14. ( J Am Heart Assoc.
2013;2:e006007 doi: 10.1161/JAHA.112.006007)
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P -selectin is a cell surface adhesion molecule that has acentral role in mediating interactions between platelets
and other cell types, such as leukocytes and the endothe-
lium.1 It is the largest of the selectins, with a mass of
140 kDa, and is stored in the a granules of unstimulated
platelets and Weibel–Palade bodies of endothelial cells. When
P-selectin is expressed on activated platelets and endothelial
cells, interaction with its primary ligand, P-selectin glycopro-
tein ligand type 1 (PSGL-1), mediates the initial tethering and
rolling process that precedes leukocyte transmigration
through the vessel wall.2,3 There also appears to be a
P-selectin-dependent pathway of fibrin formation during
coagulation; hence, both P-selectin and PSGL-1 appear to
contribute to thrombus formation and propagation.4
Modern flow-cytometric techniques allow platelets to be
analyzed in their physiological environment of whole blood with
minimal sample manipulation.5 Surface expression of P-
selectin is a marker for platelet activation, and elevated levels
have been identified in a number of conditions including
cigarette smoking,6 diabetes mellitus,7 hypertension,8 and
acute coronary syndromes.9 In addition, circulating platelet–
monocyte aggregates form by the binding of activated platelets
to leukocytes through a P-selectin-dependent mechanism.9,10
This can be readily measured by flow cytometry and has
emerged as a highly sensitive marker of platelet activation.11
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The adhesion of activated platelets to monocytes also has
important functional consequences and can induce the expres-
sion of cytokines, chemokines, adhesion molecules, and tissue
factor.12,13 Consistent with these biological effects, circulating
platelet–monocyte aggregates appear to promote atheroscle-
rotic lesion formation14 and are increased in patients with stable
coronary heart disease15 and acute coronary syndromes.9
The therapeutic potential of P-selectin antagonism has
been demonstrated by the application of specific monoclonal
antibodies that block P-selectin and PSGL-1 and are associ-
ated with reduced levels of platelet activation.9 Indeed,
P-selectin-blocking antibodies reduced arterial thrombosis,
reperfusion injury, and infarct size in mice.16 Recently small-
molecule antagonists have been developed that interact with
P-selectin and inhibit its function. PSI-697 is a novel small-
molecule selective P-selectin antagonist that reduces both
arterial and venous thrombosis in animal models.17–20
The aim of the present study was to assess the effects of
PSI-697 on platelet–monocyte aggregate formation in healthy
smokers and nonsmokers.
Methods
Subjects
In all, 25 smoking and 6 nonsmoking healthy volunteers were
recruited into the study following screening. Before study
commencement, all subjects had a normal electrocardiogram
and normal baseline measures of clinical hematology and
biochemistry variables including hemoglobin, platelet count,
renal function, glucose, and coagulation. Exclusion criteria
included intercurrent infective illness, diabetes mellitus,
hypertension, renal and hepatic impairment, asthma, bleeding
disorder, alcohol or drug misuse, recent surgical procedures,
and the use of regular medications.
The study was performed with the approval of the research
ethics committee in accordancewith theDeclaration of Helsinki
and with the written informed consent of all volunteers.
Drugs
PSI-697 (2-[4-chlorobenzyl]-3-hydroxy-7,8,9,10-tetrahydroben
zo[h] quinoline-4-carboxylic acid) is a selective antagonist of
P-selectin.17,20 For in vitro studies, PSI-697 was dissolved in
polyethylene glycol (molecular weight 400) and diluted (1:10) in
a saline vehicle. Based on previous pharmacokinetic data from
ascending-dose clinical studies, a single oral dose of 600 mg of
PSI-697 was selected to achieve a plasma concentration of
1700 ng/mL at 4 hours and 170 ng/mL at 24 hours. In a
canine thrombosis model, PSI-697 at a plasma concentration of
835 ng/mL reduced platelet–monocyte aggregate formation
(unpublished results).
Flow Cytometry
Peripheral venous blood was drawn from a large antecubital
vein with a 19-gauge needle and anticoagulated with the
direct thrombin inhibitor D-phenylalanine-L-prolyl-L-arginine
chloromethyl ketone (PPACK, 75 lmol/L; Cambridge Bio-
sciences, UK).21 Immediately following venesection, aliquots
of whole blood (500 lL) were incubated for 5 minutes in the
presence or absence of thrombin receptor-activating peptide
(TRAP; 0.1, 0.3, and 1.0 lmol/L) to induce platelet activation.
Sample aliquots (60 lL) were then incubated with anti-CD14-
PE, anti-CD42a-FITC, and isotype matched controls for
20 minutes at room temperature. Thereafter, samples were
fixed and the red cells lysed by the addition of 500 lL of
FACS-Lyse solution. Samples were then stored at 4°C and
analyzed on a FACS Calibur flow cytometer (Becton Dickin-
son) using Cell Quest software as described previously.
Samples were run at a medium flow rate until 2500
monocytes were collected. Monocytes were identified by
their forward- and side-scatter characteristics as well as by
their binding to CD14. CD42a-positive monocytes were taken
to be platelet–monocyte aggregates (PMA) and expressed as
a percentage of cells.
Measurement of Plasma PSI-697 Concentrations
PSI-697 concentrations were determined using a validated
LC/MS/MS method. Based on a sample volume of 200 lL,
the method had a lower limit of quantification of 4.0 ng/mL.
The interday coefficients of variation (CVs) and mean bias
values for the calibration standards ranged from 3.7% to 7.8%
and from 3.9% to 2.6%, respectively. The interassay CV for
the quality control samples containing PSI-697 at 12.0, 350,
and 800 ng/mL were 10.3%, 6.2%, and 7.4%, respectively.
Mean inaccuracy (bias) values were 2.5%, 5.4%, and
0.4% for 12.0, 350, and 800 ng/mL, respectively.
Study Design
In vitro studies in nonsmokers
Six healthy nonsmokers attended on a single occasion for
venipuncture after a minimum 4-hour fast. Either PSI-697
(7400 ng/mL; 20 lmol/L), the P-selectin-blocking antibody
CLB-Thromb6 (10 lg/mL) or control buffer was immediately
added to whole blood before measuring platelet–monocyte
aggregates in the presence or absence of TRAP stimulation as
described above.
Oral administration of PSI-697 in smokers
Twenty-five healthy smokers attended on 2 occasions 1 week
apart. On each occasion, they were admitted to the Edinburgh
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Clinical Research Facility for an observed overnight fast of
≥10 hours. A brief physical assessment was performed, with
recording of vital signs, 12-lead electrocardiogram, and labora-
tory evaluations of blood chemistry, hematology, coagulation,
urinalysis, and urine drug screen. Study medication was
administered at 8 AM and blood drawn at 12 PM and at 8 AM
the following morning. Heart rate, blood pressure, respiratory
rate, and body temperature were observed for 6 hours post
dosing. Subjectswere free to smoke throughout the study period
and were encouraged to smoke at least 2 cigarettes on the
morning of study, but not more than 30 minutes before dosing.
Statistical Analysis
In vitro study data are presented as meanstandard error of
the mean (SEM) and were analyzed with 2-way analysis of
variance (ANOVA) with repeated measures. For the in vivo
study, data are presented as meanstandard deviation (SD).
In this study, the change from baseline values for PMA were
analyzed using a mixed-effects analysis of covariance (AN-
COVA) that accounts for repeated measures taken within a
2-period crossover design. Baseline values were included in
the model as a covariate. Treatment (PSI-697 or placebo),
time, period, and sequence as well as the interaction between
time and treatment were included in the model as fixed
effects. Subject was a random effect in the model. Statistical
significance was taken as a 2-sided P value <0.05.
Results
In Vitro Studies in Nonsmokers
In vitro analyses were conducted in 6 healthy nonsmoking
male and female volunteers aged between 18 and 30 years.
The in vitro addition of TRAP produced a concentration-
dependent increase in platelet–monocyte aggregate forma-
tion (P<0.001; Figure 1). The P-selectin-blocking antibody
CLB-Thromb6 markedly inhibited platelet–monocyte aggre-
gate formation in the presence and absence of TRAP (P<0.05).
In contrast, we observed no difference in either unstimulated
or stimulated platelet–monocyte aggregates following the
addition of PSI-697 compared with placebo control.
Oral Administration of PSI-697 in Smokers
One hundred twenty-two smokers were screened to identify
25 volunteers to participate in the study. Twenty-four of the
25 recruited volunteers completed the study visits; 1 subject
declined to participate further after 1 visit for personal
reasons. Subjects smoked 184 cigarettes daily and were
white men aged 349 years (range, 18 to 55 years) with a
body mass index of 243 kg/m2.
Following oral administration, mean (SD) plasma PSI-697
concentrations rose to 19061511 ng/mL at 4 hours and
subsequently fell to 8352 ng/mL at 24 hours. PSI-697 was
well tolerated, with no clinically significant symptoms or
changes in hematological, biochemical, or electrocardio-
graphic variables.
Platelet–monocyte aggregates increased in a concentra-
tion-dependent manner with the addition of ex vivo TRAP
(Figure 2). Platelet–monocyte aggregate measurements ran-
ged from 3.7% to 41.4% for unstimulated samples and from
8.2% to 94.8% for stimulated samples. There was no
difference in stimulated and unstimulated platelet–monocyte
aggregates between placebo and PSI-697 (P>0.05; Figure 3).
At 4 hours, there was a difference estimate of 1.2% (95%
confidence interval [CI], 3.6% to 1.1%; P=0.3013) of
platelet–monocyte aggregation from baseline. At 24 hours,
there was a difference estimate of 0.9% (90% CI, 2.9% to
4.7%; P=0.6304) of platelet–monocyte aggregation. Of all of
the fixed effects included in our ANCOVA model, only the
baseline PMA value was significant (P<0.0001).
Discussion
We have demonstrated that oral administration of the
P-selectin antagonist PSI-697 was well tolerated and caused
no significant adverse effects in otherwise healthy smokers.
Figure 1. Platelet–monocyte aggregates (%) following thrombin
receptor-activating peptide (TRAP) activation in the presence of
saline (open circles), the P-selectin antagonist PSI-697 (20 lmol/L
[7400 ng/mL]; closed circles), and the P-selectin-blocking antibody
CLB-Thomb6 (10 lg/mL; closed square). P<0.001 for platelet–
monocyte aggregate formation in response to TRAP; P<0.001,
CLB-Thromb6 vs placebo; P>0.05, PSI-697 vs placebo.
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However, PSI-697 was unable to block the P-selectin-PSGL-1
binding of activated platelets to monocytes, either in vitro or
in vivo, at the dose tested. This suggests a lack of efficacy of
PSI-697 or an inability of this biomarker to assess P-selectin
antagonism in humans.
The therapeutic approach of blocking P-selectin action has
several potentially beneficial effects in the prevention or
treatment of cardiovascular disease. P-selectin enables the
tethering and rolling of leukocytes along the vessel wall2,3 and
promotes the generation of prothrombotic microparticles,
leading to the development of thrombosis.22 Interruption of
this early event in lesion formation may prevent downstream
amplification of the inflammatory and thrombotic processes
that contribute to atherosclerotic lesion growth, development,
and instability.9 Moreover, studies have suggested that there
is a P-selectin-dependent pathway of fibrin formation during
coagulation, and hence both P-selectin and PSGL-1 contribute
to thrombus formation and propagation.4,22–25
We9 and others10–13 have previously demonstrated that
P-selectin interaction with its primary ligand, PSGL-1, medi-
ates the majority of platelet–monocyte aggregate formation.
Platelet–monocyte aggregate formation is a measure of in
vivo platelet activation that is readily undertaken, is repro-
ducible, and can be augmented by the addition of exogenous
agonists.21 Therefore, this would seem to be the ideal
biomarker to determine the efficacy of P-selectin antagonism.
Why then did we not see an effect of PSI-697 on platelet–
monocyte aggregates?
Did we achieve sufficient plasma PSI-697 concentrations
following oral dosing? We based the oral dosing on previous
phase I pharmacokinetic data in health volunteers. To avoid
any interaction with diet that could affect bioavailability,
subjects were fasted prior to drug administration. Four hours
following oral administration, we achieved the anticipated
plasma PSI-697 concentration of 1906 ng/mL. This concen-
tration should be sufficient to inhibit P-selectin-mediated
platelet–monocyte aggregate formation, as it was higher than
the in vivo concentration that inhibited platelet–monocyte
aggregate formation by 30% in a canine thrombosis model
(unpublished observations). Therefore, we concluded that the
absence of a demonstrable effect was unlikely to be a result
of inadequate dosing or lack of bioavailability. This could be
confirmed in future studies by determination of ligand binding
of PSI-697 at equivalent plasma concentrations.
Are platelet–monocyte aggregates an appropriate biomar-
ker of P-selectin activity? To confirm our current model, we
measured in vitro basal and stimulated platelet–monocyte
aggregate formation in the presence and absence of
P-selectin antagonism with either PSI-697 or a P-selectin-
blocking antibody. While acknowledging that our study may
have been underpowered to detect small differences, the
addition of PSI-697 had no apparent effect on platelet–
monocyte aggregation. In contrast, the P-selectin-blocking
antibody markedly inhibited platelet–monocyte aggregate
formation. This reaffirms our previous findings9 and those of
others10–13 that platelet–monocyte aggregate formation is a
predominantly P-selectin-mediated process. We acknowledge
there remains a small but persistent residual proportion of
platelet–monocyte aggregates that are formed by P-selectin-
independent mechanisms.9 Blockade of the P-selectin path-
way may upregulate these other mechanisms and allow
aggregate formation. However, the P-selectin-blocking
antibody was able to achieve marked inhibition, and if PSI-
697 was efficacious, then we would have anticipated a
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Figure 2. Platelet–monocyte aggregates (%) following thrombin
receptor-activating peptide (TRAP) activation 4 hours following oral
administration of the P-selectin antagonist PSI-697 (600 mg; closed
circles) or matched placebo (open circles). P<0.001 for platelet–
monocyte aggregate formation in response to TRAP; P>0.05, PSI-697
vs placebo.
Figure 3. Individual values for absolute change from baseline in
platelet–monocyte aggregates 4 hours (left panel) and 24 hours
(right panel) after oral administration of the P-selectin antagonist
PSI-697 or matched placebo.
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demonstrable reduction in aggregate formation. We therefore
believe that the biomarker used in this study was appropriate.
Why does PSI-697 not block the formation of platelet–
monocyte aggregates in humans? The present study is the first
to assess the effects of oral administration of PSI-697 on
platelet–monocyte aggregates in humans. In several preclinical
models, PSI-697 at concentrations as low as 400 ng/mL has
demonstrated favorable reductions in both arterial and venous
thrombosis.17–20 Oral administration of PSI-697 to rodents
reduced inflammation and thrombus formation that importantly
was not associated with prolonged bleeding times.17,19 In
baboon models of venous thrombosis, PSI-697 decreased
vascular inflammation, modified thrombogenesis, and encour-
aged recanalization of thrombosed veins without measurable
anticoagulation.18 Our study did not assess the effects of PSI-
697 on vascular thrombosis and focused on the binding of
platelets to monocytes. Thus, there seems to be inconsistency
between the antithrombotic effects of PSI-697 and its ability to
inhibit platelet–monocyte aggregates. Indeed, we have dem-
onstrated that PSI-697 reduces ex vivo thrombus formation in
humans at concentrations achieved in the current study.26
Using the Badimon ex vivomodel of thrombosis, we have shown
that, under dynamic flow conditions at both high and low shear
stress, PSI-697 caused a reduction in thrombus formation.
How do we account for the discrepancy between throm-
bosis and platelet–monocyte aggregate data? This is difficult
to reconcile but could include an off-target effect of PSI-697
that has an antithrombotic action mediated through a non-P-
selectin pathway. Alternatively, the interaction of PSI-697 with
P-selectin may be incomplete in certain settings. There are 2
ligand recognition sites on P-selectin: sialyl Lewis x and PSGL-
1 core protein.27 Sialyl Lewis x is a carbohydrate on the cell
surface attached to an O-glycan and plays a vital role in cell
recognition processes. It is this component that PSI-697
mimics and causes P-selectin antagonism. However, it may be
that platelet–monocyte aggregate formation does not require
binding of both sites and may explain the apparent contra-
dictory findings with the P-selectin-blocking antibody. This
hypothesis requires further study.
Smoking is associated with accelerated atherosclerotic
development,28 with an increase in markers of systemic
inflammation. We have previously demonstrated that cigarette
smoking is associated with increased baseline platelet
activation with modest increases in platelet–monocyte aggre-
gates.29 In the present study, many of the cigarette smokers
had low numbers of platelet–monocyte aggregates, contrast-
ing with our previous findings. We believe that this is likely to
reflect the strict inclusion criteria of the present study and
that we selected a “healthier” population of smokers than
found in our previous study. We do not believe this detracts
from our findings because we also assessed TRAP-induced
platelet–monocyte aggregates and achieved very high levels
of aggregate formation in vitro. Nonetheless, further studies
examining the potential effects of PSI-697 with agonists other
than TRAP and in populations with higher baseline levels of
platelet–monocyte aggregates, such as patients with diabetes
mellitus or established vascular disease, would provide useful
confirmation of our findings.
Conclusions
The novel small-molecule P-selectin antagonist PSI-697 did
not inhibit basal or stimulated platelet–monocyte aggregate
formation in humans at the dose tested. Its clinical efficacy
remains to be established.
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